CoChat

Cathelicidin Peptide LL-37 Modulates TREM-1 Expression and Inflammatory Responses to Microbial Compounds

Amatngalim, Gimano D., Nijnik, Anastasia, Hiemstra, Pieter S., Hancock, Robert E. W. · 2011 · Inflammation
Cited by 24

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10753-010-9248-6

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 65

  1. Nijnik, A., and R.E.W. Hancock. 2009. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Current Opinion in Hematology 16: 41–47. · DOI · Paper page
  2. Larrick, J.W., J. Lee, S. Ma, X. Li, U. Francke, S.C. Wright, and R.F. Balint. 1996. Structural, functional analysis and localization of the human CAP18 gene. FEBS Letters 398: 74–80. · DOI · Paper page
  3. Bals, R., D.J. Weiner, R.L. Meegalla, and J.M. Wilson. 1999. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. Journal of Clinical Investigation 103: 1113–1117. · DOI · Paper page
  4. Schaller-Bals, S., A. Schulze, and R. Bals. 2002. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. American Journal of Respiratory and Critical Care Medicine 165: 992–995. · DOI · Paper page
  5. Bowdish, D.M., D.J. Davidson, Y.E. Lau, K. Lee, M.G. Scott, and R.E. Hancock. 2005. Impact of LL-37 on anti-infective immunity. Journal of Leukocyte Biology 77: 451–459. · DOI · Paper page
  6. Mookherjee, N., K.L. Brown, D.M. Bowdish, S. Doria, R. Falsafi, K. Hokamp, F.M. Roche, R. Mu, G.H. Doho, J. Pistolic, J.P. Powers, J. Bryan, F.S. Brinkman, and R.E. Hancock. 2006. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. Journal of Immunology 176: 2455–2464. · DOI · Paper page
  7. Kandler, K., R. Shaykhiev, P. Kleemann, F. Klescz, M. Lohoff, C. Vogelmeier, and R. Bals. 2006. The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. International Immunology 18: 1729–1736. · DOI
  8. Molhoek, E.M., A.L. den Hertog, A.M. de Vries, K. Nazmi, E.C. Veerman, F.C. Hartgers, M. Yazdanbakhsh, F.J. Bikker, and D. van der Kleij. 2009. Structure–function relationship of the human antimicrobial peptide LL-37 and LL-37 fragments in the modulation of TLR responses. Biological Chemistry 390: 295–303. · DOI
  9. Nell, M.J., G.S. Tjabringa, A.R. Wafelman, R. Verrijk, P.S. Hiemstra, J.W. Drijfhout, and J.J. Grote. 2006. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27: 649–660. · DOI · Paper page
  10. Scott, M.G., D.J. Davidson, M.R. Gold, D. Bowdish, and R.E. Hancock. 2002. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. Journal of Immunology 169: 3883–3891. · DOI · Paper page
  11. Pinheiro da Silva, F., R.L. Gallo, and V. Nizet. 2009. Differing effects of exogenous or endogenous cathelicidin on macrophage toll-like receptor signaling. Immunology and Cell Biology 87(6): 496–500. · DOI
  12. Di Nardo, A., M.H. Braff, K.R. Taylor, C. Na, R.D. Granstein, J.E. McInturff, S. Krutzik, R.L. Modlin, and R.L. Gallo. 2007. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. Journal of Immunology 178: 1829–1834. · DOI · Paper page
  13. Tjabringa, G.S., J. Aarbiou, D.K. Ninaber, J.W. Drijfhout, O.E. Sorensen, N. Borregaard, K.F. Rabe, and P.S. Hiemstra. 2003. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. Journal of Immunology 171: 6690–6696. · DOI · Paper page
  14. Elssner, A., M. Duncan, M. Gavrilin, and M.D. Wewers. 2004. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. Journal of Immunology 172: 4987–4994. · DOI · Paper page
  15. Niyonsaba, F., A. Someya, M. Hirata, H. Ogawa, and I. Nagaoka. 2001. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. European Journal of Immunology 31: 1066–1075. · DOI · Paper page
  16. Schiemann, F., E. Brandt, R. Gross, B. Lindner, J. Mittelstadt, C.P. Sommerhoff, J. Schulmistrat, and F. Petersen. 2009. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: Counter-regulation by CXCL4. Journal of Immunology 183: 2223–2231. · DOI
  17. Ganguly, D., G. Chamilos, R. Lande, J. Gregorio, S. Meller, V. Facchinetti, B. Homey, F.J. Barrat, T. Zal, and M. Gilliet. 2009. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. The Journal of Experimental Medicine 206: 1983–1994. · DOI · Paper page
  18. Zhang, Z., G. Cherryholmes, and J.E. Shively. 2008. Neutrophil secondary necrosis is induced by LL-37 derived from cathelicidin. Journal of Leukocyte Biology 84: 780–788. · DOI
  19. Barlow, P.G., Y. Li, T.S. Wilkinson, D.M. Bowdish, Y.E. Lau, C. Cosseau, C. Haslett, A.J. Simpson, R.E. Hancock, and D.J. Davidson. 2006. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. Journal of Leukocyte Biology 80: 509–520. · DOI · Paper page
  20. Nagaoka, I., H. Tamura, and M. Hirata. 2006. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. Journal of Immunology 176: 3044–3052. · DOI · Paper page
  21. Yu, J., N. Mookherjee, K. Wee, D.M. Bowdish, J. Pistolic, Y. Li, L. Rehaume, and R.E. Hancock. 2007. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. Journal of Immunology 179: 7684–7691. · DOI · Paper page
  22. Mookherjee, N., P. Hamill, J. Gardy, D. Blimkie, R. Falsafi, A. Chikatamarla, D.J. Arenillas, S. Doria, T.R. Kollmann, and R.E. Hancock. 2009. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Molecular Biosystems 5: 483–496. · DOI
  23. An, L.L., Y.H. Yang, X.T. Ma, Y.M. Lin, G. Li, Y.H. Song, and K.F. Wu. 2005. LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leukemia Research 29: 535–543. · DOI
  24. Kurosaka, K., Q. Chen, F. Yarovinsky, J.J. Oppenheim, and D. Yang. 2005. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. Journal of Immunology 174: 6257–6265. · DOI · Paper page
  25. Yamasaki, K., A. Di Nardo, A. Bardan, M. Murakami, T. Ohtake, A. Coda, R.A. Dorschner, C. Bonnart, P. Descargues, A. Hovnanian, V.B. Morhenn, and R.L. Gallo. 2007. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Natural Medicines 13: 975–980. · DOI · Paper page
  26. Hamill, P., K. Brown, H. Jenssen, and R.E. Hancock. 2008. Novel anti-infectives: Is host defence the answer? Current Opinion in Biotechnology 19: 628–636. · DOI
  27. Hancock, R.E., and H.G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology 24: 1551–1557. · DOI · Paper page
  28. Mookherjee, N., L.M. Rehaume, and R.E. Hancock. 2007. Cathelicidins and functional analogues as antisepsis molecules. Expert Opinion on Therapeutic Targets 11: 993–1004. · DOI
  29. Nijnik, A., L. Madera, S. Ma, M. Waldbrook, M.R. Elliott, D.M. Easton, M.L. Mayer, S.C. Mullaly, J. Kindrachuk, H. Jenssen, and R.E. Hancock. 2010. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. Journal of Immunology 184: 2539–2950. · DOI · Paper page
  30. Klesney-Tait, J., I.R. Turnbull, and M. Colonna. 2006. The TREM receptor family and signal integration. Nature Immunology 7: 1266–1273. · DOI · Paper page
  31. Chen, L.C., J.D. Laskin, M.K. Gordon, and D.L. Laskin. 2008. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Experimental and Molecular Pathology 84: 145–155. · DOI
  32. Gibot, S., C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, F. Benigni, G.C. Faure, M.C. Bene, P. Panina-Bordignon, N. Passini, and B. Levy. 2006. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infection and Immunity 74: 2823–2830. · DOI
  33. Haselmayer, P., L. Grosse-Hovest, P. von Landenberg, H. Schild, and M.P. Radsak. 2007. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 110: 1029–1035. · DOI · Paper page
  34. Wong-Baeza, I., N. Gonzalez-Roldan, E. Ferat-Osorio, N. Esquivel-Callejas, R. Aduna-Vicente, L. Arriaga-Pizano, H. Astudillo-de la Vega, M.A. Villasis-Keever, R. Torres-Gonzalez, I. Estrada-Garcia, C. Lopez-Macias, and A. Isibasi. 2006. Triggering receptor expressed on myeloid cells (TREM-1) is regulated post-transcriptionally and its ligand is present in the sera of some septic patients. Clinical and Experimental Immunology 145: 448–455. · DOI
  35. Mohamadzadeh, M., S.S. Coberley, G.G. Olinger, W.V. Kalina, G. Ruthel, C.L. Fuller, D.L. Swenson, W.D. Pratt, D.B. Kuhns, and A.L. Schmaljohn. 2006. Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by Marburg and Ebola viruses. Journal of Virology 80: 7235–7244. · DOI
  36. Radsak, M.P., H.R. Salih, H.G. Rammensee, and H. Schild. 2004. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: Differential regulation of activation and survival. Journal of Immunology 172: 4956–4963. · DOI · Paper page
  37. Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103–1107. · DOI · Paper page
  38. Netea, M.G., T. Azam, G. Ferwerda, S.E. Girardin, S.H. Kim, and C.A. Dinarello. 2006. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. Journal of Leukocyte Biology 80: 1454–1461. · DOI · Paper page
  39. Schenk, M., A. Bouchon, F. Seibold, and C. Mueller. 2007. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. Journal of Clinical Investigation 117: 3097–3106. · DOI · Paper page
  40. Gibot, S., F. Massin, C. Alauzet, M. Derive, C. Montemont, S. Collin, S. Fremont, and B. Levy. 2010. Effects of the TREM-1 pathway modulation during hemorrhagic shock in rats. Shock 32(6): 633–637. · DOI
  41. Lagler, H., O. Sharif, I. Haslinger, U. Matt, K. Stich, T. Furtner, B. Doninger, K. Schmid, R. Gattringer, A.F. de Vos, and S. Knapp. 2009. TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. Journal of Immunology 183: 2027–2036. · DOI · Paper page
  42. Gibot, S., F. Massin, M. Marcou, V. Taylor, R. Stidwill, P. Wilson, M. Singer, and G. Bellingan. 2007. TREM-1 promotes survival during septic shock in mice. European Journal of Immunology 37: 456–466. · DOI
  43. Darveau, R.P., and R.E. Hancock. 1983. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. Journal of Bacteriology 155: 831–838. · DOI · Paper page
  44. Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29: e45. · DOI · Paper page
  45. Knapp, S., S. Gibot, A. de Vos, H.H. Versteeg, M. Colonna, and T. van der Poll. 2004. Cutting edge: Expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. Journal of Immunology 173: 7131–7134. · DOI
  46. Gomez-Pina, V., A. Soares-Schanoski, A. Rodriguez-Rojas, C. Del Fresno, F. Garcia, M.T. Vallejo-Cremades, I. Fernandez-Ruiz, F. Arnalich, P. Fuentes-Prior, and E. Lopez-Collazo. 2007. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. Journal of Immunology 179: 4065–4073. · DOI · Paper page
  47. Girardin, S.E., L.H. Travassos, M. Herve, D. Blanot, I.G. Boneca, D.J. Philpott, P.J. Sansonetti, and D. Mengin-Lecreulx. 2003. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. The Journal of Biological Chemistry 278: 41702–41708. · DOI · Paper page
  48. Kanneganti, T.D., M. Lamkanfi, and G. Nunez. 2007. Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549–559. · DOI · Paper page
  49. Girardin, S.E., I.G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D.J. Philpott, and P.J. Sansonetti. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. The Journal of Biological Chemistry 278: 8869–8872. · DOI · Paper page
  50. Dziarski, R., and D. Gupta. 2005. Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: A reevaluation. Infection and Immunity 73: 5212–5216. · DOI · Paper page
  51. Travassos, L.H., S.E. Girardin, D.J. Philpott, D. Blanot, M.A. Nahori, C. Werts, and I.G. Boneca. 2004. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Reports 5: 1000–1006. · DOI · Paper page
  52. Zahringer, U., B. Lindner, S. Inamura, H. Heine, and C. Alexander. 2008. TLR2—Promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213: 205–224. · DOI · Paper page
  53. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nature Reviews. Immunology 4: 499–511. · DOI · Paper page
  54. Rittirsch, D., M.A. Flierl, and P.A. Ward. 2008. Harmful molecular mechanisms in sepsis. Nature Reviews. Immunology 8: 776–787. · DOI · Paper page
  55. Riedemann, N.C., R.F. Guo, and P.A. Ward. 2003. The enigma of sepsis. Journal of Clinical Investigation 112: 460–467. · DOI
  56. Mookherjee, N., H.L. Wilson, S. Doria, Y. Popowych, R. Falsafi, J.J. Yu, Y. Li, S. Veatch, F.M. Roche, K.L. Brown, F.S. Brinkman, K. Hokamp, A. Potter, L.A. Babiuk, P.J. Griebel, and R.E. Hancock. 2006. Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. Journal of Leukocyte Biology 80: 1563–1574. · DOI · Paper page
  57. Nijnik, A., J. Pistolic, A. Wyatt, S. Tam, and R.E. Hancock. 2009. Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. Journal of Immunology 183: 5788–5798. · DOI
  58. Heng, Z., Heiderscheidt, C.A., Joo, M., Gao, X., Knezevic, N., Mehta, D., and Sadikot, R.T. 2010. MyD88-dependent and -independent activation of TREM-1 via specific TLR ligands. Eur J Immunol 40(1) :162–171. · DOI
  59. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443–451. · DOI · Paper page
  60. Yoshimura, A., E. Lien, R.R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golenbock. 1999. Cutting edge: Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. Journal of Immunology 163: 1–5. · DOI · Paper page
  61. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C.J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. The Journal of Biological Chemistry 274: 17406–17409. · DOI · Paper page
  62. Carneiro, L.A., L.H. Travassos, and D.J. Philpott. 2004. Innate immune recognition of microbes through Nod1 and Nod2: Implications for disease. Microbes and Infection 6: 609–616. · DOI
  63. Lau, Y.E., A. Rozek, M.G. Scott, D.L. Goosney, D.J. Davidson, and R.E. Hancock. 2005. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infection and Immunity 73: 583–591. · DOI
  64. Mookherjee, N., D.N. Lippert, P. Hamill, R. Falsafi, A. Nijnik, J. Kindrachuk, J. Pistolic, J. Gardy, P. Miri, M. Naseer, L.J. Foster, and R.E. Hancock. 2009. Intracellular receptor for human host defense peptide LL-37 in monocytes. Journal of Immunology 183: 2688–2696. · DOI · Paper page
  65. Sandgren, S., A. Wittrup, F. Cheng, M. Jonsson, E. Eklund, S. Busch, and M. Belting. 2004. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. The Journal of Biological Chemistry 279: 17951–17956. · DOI · Paper page

Cited by

See all 24

Metadata

Authors
Amatngalim, G. D., Nijnik, A., Hiemstra, P. S., & Hancock, R. E. W.
Venue
Inflammation
Published
2010-09-02
Volume
34
Issue
5
Pages
412-425
ISSN
  • 0360-3997
  • 1573-2576
Cited by
24
References
7
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cathelicidin Peptide LL-37 Modulates TREM-1 Expression and Inflammatory Responses to Microbial Compounds. https://app.cochat.ai/papers/10.1007/s10753-010-9248-6
The paper
Amatngalim, G. D., Nijnik, A., Hiemstra, P. S., & Hancock, R. E. W. (2011). Cathelicidin Peptide LL-37 Modulates TREM-1 Expression and Inflammatory Responses to Microbial Compounds. Inflammation. https://doi.org/10.1007/s10753-010-9248-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.